Completed PHASE2 INTERVENTIONAL NCT01127555

Salvage mFOLFOX in BTC After Failure of Gemcitabine

Phase II Study of Salvage mFOLFOX(5-fluorouracil, Leucovorin, Oxaliplatin) in Patients With Unresectable Biliary Tract Cancer (BTC) Who Had Failed Gemcitabine

Sponsor: Chung-Ang University

Conditions Unresectable Biliary Tract Cancer

Interventions 5-fluorouracil, leucovorin, oxaliplatin

Updated 6 times since 2017 Last updated: Oct 6, 2013 Started: Apr 30, 2010 Primary completion: Jun 30, 2012 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01127555, this PHASE2 trial focuses on Unresectable Biliary Tract Cancer and remains completed. Sponsored by Chung-Ang University, it has been updated 6 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chung-Ang University
Dong-A University Hospital
Gyeongsang National University Hospital
Samsung Medical Center

Data source: Chung-Ang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Yongsan, South Korea